Market closedNon-fractional

AC Immune/ACIU

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Ticker

ACIU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Lausanne, Switzerland

Employees

147

AC Immune Metrics

BasicAdvanced
$399M
Market cap
-
P/E ratio
-$0.69
EPS
1.30
Beta
-
Dividend rate
$399M
1.3
7.779
7.502
1.836
2.301
-488.01%
-20.85%
-36.68%
20.49
2.61
4.01
-6.982
276.14%
-25.90%
67.49%
-14.53%

What the Analysts think about AC Immune

Analyst Ratings

Majority rating from 4 analysts.
Buy

AC Immune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
CHF 0
-100.00%
Net income
-CHF 18M
278.72%
Profit margin
0.00%
-100.00%

AC Immune Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 32.92%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-CHF 0.20
-CHF 0.18
-CHF 0.05
-CHF 0.18
-
Expected
-CHF 0.19
CHF 0.03
-CHF 0.11
-CHF 0.14
CHF 0.40
Surprise
3.67%
-754.26%
-54.25%
32.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AC Immune stock?

AC Immune (ACIU) has a market cap of $399M as of July 06, 2024.

What is the P/E ratio for AC Immune stock?

The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of July 06, 2024.

Does AC Immune stock pay dividends?

No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next AC Immune dividend payment date?

AC Immune (ACIU) stock does not pay dividends to its shareholders.

What is the beta indicator for AC Immune?

AC Immune (ACIU) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell AC Immune stock

Buy or sell AC Immune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing